A Phase 1 interventional study of YM178 in Healthy Volunteer and Pharmacokinetics of YM178, sponsored by Astellas Pharma Inc. Completed at 1 site in Japan. Open to participants aged 20 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-17.
Sponsored by Astellas Pharma Inc · Phase 1 and Interventional
The purpose of the study is to evaluate the effect of food intake on the pharmacokinetics of YM178 in healthy, non-elderly adult subjects.
Astellas Pharma Inc is the lead sponsor of 512 studies on the registry; 4 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 19 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
3 way cross-over. Fasting, normal diet and high-fat diet
Drug: YM178
3 way cross-over. Fasting, normal diet and high-fat diet
Drug: YM178
oral
Also known as: mirabegron
Plasma concentration of unchanged YM178
Time frame: Up to 96 hours post dose
Urinary concentration of unchanged YM178
Time frame: Up to 96 hours post dose
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Astellas Pharma Inc